SHIfT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) is the first study to assess whether heart rate reduction by direct sinus node inhibition can decrease cardiovascular outcomes in patients with chronic heart failure and left ventricular systolic dysfunction.1

SHIFT

February 2012
European Medicines Agency granted the indication of ivabradine in chronic heart failure

[symptomatic patients (NYHA II-IV) in sinus rhythm with heart rate ≥75 bpm]2

May 2012
ESC guidelines for the diagnosis and management of heart failure included ivabradine in the algorithm for the treatment of chronic heart failure

[symptomatic patients (NYHA II-IV) in sinus rhythm with heart rate ≥70 bpm]3

Ivabradine is the first innovative drug after more than a decade to improve the prognosis, to reduce hospitalizations, and to improve the quality of life of heart failure patients.


  1. Swedberg K, et al. Lancet. 2010;376(9744):875-885.
  2. Procoralan Summary of Product Characteristics. (EUROPE – latest update of January 2015)
  3. McMurray J, et al. Eur Heart J. 2012;33:1787-1847.

Ivabradine is available under the following brand names: Procoralan®, Coralan®, Corlanor®, Corlentor®, and Coraxan®.